Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Nov;22(11):1530-1540.
doi: 10.1016/S1470-2045(21)00471-X. Epub 2021 Oct 14.

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Dean A Fennell  1 , Sean Ewings  2 , Christian Ottensmeier  3 , Raffaele Califano  4 , Gerard G Hanna  5 , Kayleigh Hill  2 , Sarah Danson  6 , Nicola Steele  7 , Mavis Nye  8 , Lucy Johnson  2 , Joanne Lord  9 , Calley Middleton  2 , Peter Szlosarek  10 , Sam Chan  11 , Aarti Gaba  12 , Liz Darlison  13 , Peter Wells-Jordan  14 , Cathy Richards  14 , Charlotte Poile  12 , Jason F Lester  15 , Gareth Griffiths  2 ; CONFIRM trial investigators
Collaborators, Affiliations
Clinical Trial

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Dean A Fennell et al. Lancet Oncol. 2021 Nov.

Erratum in

Abstract

Background: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab, an anti-PD-1 antibody, in these patients.

Methods: This was a multicentre, placebo-controlled, double-blind, parallel group, randomised, phase 3 trial done in 24 hospitals in the UK. Adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1, with histologically confirmed pleural or peritoneal mesothelioma, who had received previous first-line platinum-based chemotherapy and had radiological evidence of disease progression, were randomly assigned (2:1) to receive nivolumab at a flat dose of 240 mg every 2 weeks over 30 min intravenously or placebo until disease progression or a maximum of 12 months. The randomisation sequence was generated within an interactive web response system (Alea); patients were stratified according to epithelioid versus non-epithelioid histology and were assigned in random block sizes of 3 and 6. Participants and treating clinicians were masked to group allocation. The co-primary endpoints were investigator-assessed progression-free survival and overall survival, analysed according to the treatment policy estimand (an equivalent of the intention-to-treat principle). All patients who were randomly assigned were included in the safety population, reported according to group allocation. This trial is registered with Clinicaltrials.gov, NCT03063450.

Findings: Between May 10, 2017, and March 30, 2020, 332 patients were recruited, of whom 221 (67%) were randomly assigned to the nivolumab group and 111 (33%) were assigned to the placebo group). Median follow-up was 11·6 months (IQR 7·2-16·8). Median progression-free survival was 3·0 months (95% CI 2·8-4·1) in the nivolumab group versus 1·8 months (1·4-2·6) in the placebo group (adjusted hazard ratio [HR] 0·67 [95% CI 0·53-0·85; p=0·0012). Median overall survival was 10·2 months (95% CI 8·5-12·1) in the nivolumab group versus 6·9 months (5·0-8·0) in the placebo group (adjusted HR 0·69 [95% CI 0·52-0·91]; p=0·0090). The most frequently reported grade 3 or worse treatment-related adverse events were diarrhoea (six [3%] of 221 in the nivolumab group vs two [2%] of 111 in the placebo group) and infusion-related reaction (six [3%] vs none). Serious adverse events occurred in 90 (41%) patients in the nivolumab group and 49 (44%) patients in the placebo group. There were no treatment-related deaths in either group.

Interpretation: Nivolumab represents a treatment that might be beneficial to patients with malignant mesothelioma who have progressed on first-line therapy.

Funding: Stand up to Cancer-Cancer Research UK and Bristol Myers Squibb.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests DAF reports grants from Astex Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, and Bayer; personal fees from Aldeyra, Inventiva, and Paredox; non-financial support from Clovis, Eli Lilly, and Bristol Myers Squibb; and personal fees and non-financial support from Roche, during the study. GG reports grants from Jannsen-Cilag, Novartis, Astex, Roche, Heartflow, Bristol Myers Squibb, BioNtech; grants and personal fees from AstraZeneca; and personal fees from Celldex, outside the submitted work. JL reports grants from Cancer Research UK and non-financial support from Bristol Myers Squibb, during the study. CO reports personal fees from Bristol Myers Squibb, outside the submitted work. RC reports personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, and AstraZeneca, during the study. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
Trial profile
Figure 2
Figure 2
Kaplan–Meier curves of progression-free survival (A) and overall survival (B) HR=hazard ratio. Shaded areas represent 95% CIs.
Figure 3
Figure 3
Forest plots showing subgroup analyses of progression-free survival (A) and overall survival (B) HR=hazard ratio. NE=not estimable.
See this image and copyright information in PMC

Comment in

References

    1. Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475–488. - PubMed
    1. Vogelzang NJ, Rusthoven JJ, Symanowski J. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644. - PubMed
    1. Krug LM, Kindler HL, Calvert H. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015;16:447–456. - PubMed
    1. Maio M, Scherpereel A, Calabrò L. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18:1261–1273. - PubMed
    1. Mansfield AS, Roden AC, Peikert T. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014;9:1036–1040. - PMC - PubMed

Publication types

MeSH terms

Associated data